SBIR-STTR Award

Purification of HTLV-I recombinant envelope antigen
Award last edited on: 12/12/2006

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$350,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Chung-Ho Hung

Company Information

Cambridge BioTech Corporation (AKA: Cambridge Bioscience Corporation))

365 Plantation Street One Biotech Park
Worcester, MA 01605
   (508) 797-5777
   N/A
   N/A
Location: Multiple
Congr. District: 02
County: Worcester

Phase I

Contract Number: 1R43AI026417-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1988
Phase I Amount
$50,000
The long term objective of the research initiated by this proposal is to develop an improved diagnostic assay for detection of antibodies to HTLV-I in human sera using recombinant DNA derived antigens. HTLV-I is a human retrovirus that has been shown to cause a form of adult T-cell leukemia, and has been linked by some researchers to a number of neurotropic diseases. Infection is spread primarily through intimate personal contact or direct blood contact. An assay to detect evidence of infection by HTLV-I must have excellent sensitivity and specificity characteristics, an be suitable for large scale automated analysis. Key components in the development of such an assay are procedures for large scale fermentation o the E. coli cultures producing the antigen, and procedures for antigen purification. In general, recombinant DNA derived proteins expressed in E coli have proven to be particularly difficult to purify because of their poor solubility and tendency to form aggregates in the absence of strong denaturants. The research plan in this proposal will make use of conventional protein purification methodology, novel protein modification methods that allow solubility in non- denaturing buffers, and high performance chromatography to purify HTLV-I recombinant envelope antigens.National Institute of Allergy and Infectious Diseases (NIAID)

Phase II

Contract Number: 2R44AI026417-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1989
(last award dollars: 1990)
Phase II Amount
$300,000

The long term objective of the research initiated by this proposal is to develop an improved diagnostic assay for detection of antibodies to HTLV-I in human sera using recombinant DNA derived antigens. HTLV-I is a human retrovirus that has been shown to cause a form of adult T-cell leukemia, and has been linked by some researchers to a number of neurotropic diseases. Infection is spread primarily through intimate personal contact or direct blood contact. An assay to detect evidence of infection by HTLV-I must have excellent sensitivity and specificity characteristics, and be suitable for large scale automated analysis. Key components in the development of such an assay are procedures for large scale fermentation of the E. coli cultures producing the antigen, and procedures for antigen purification. In general, recombinant DNA derived proteins expressed in E. coli have proven to be particularly difficult to purify because of their poor solubility and tendency to form aggregates in the absence of strong denaturants. The research plan in this proposal will make use of conventional protein purification methodology, novel protein modification methods that allow solubility in non- denaturing buffers, and high performance chromatography to purify HTLV-I recombinant envelope antigens